Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 15;209(4):362-373.
doi: 10.1164/rccm.202307-1154WS.

Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report

Sydney B Montesi  1 , Christian R Gomez  2 , Michael Beers  3 , Robert Brown  4 , Ishanu Chattopadhyay  5 , Kevin R Flaherty  6 , Christine Kim Garcia  7 , Brigitte Gomperts  8 , Lida P Hariri  1   9 , Cory M Hogaboam  10 , R Gisli Jenkins  11 , Naftali Kaminski  12 , Grace Hyun J Kim  13   14 , Melanie Königshoff  15 , Martin Kolb  16 , Darrell N Kotton  17 , Jonathan A Kropski  18 , Joseph Lasky  19   20 , Chelsea M Magin  21   22   23 , Toby M Maher  24 , Mark McCormick  19 , Bethany B Moore  25 , Cheryl Nickerson-Nutter  26 , Justin Oldham  6 , Anna J Podolanczuk  27 , Ganesh Raghu  28 , Ivan Rosas  29 , Steven M Rowe  30   31 , William T Schmidt  19 , David Schwartz  32 , Jessica E Shore  19 , Cathie Spino  33 , J Matthew Craig  2 , Fernando J Martinez  27
Affiliations

Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report

Sydney B Montesi et al. Am J Respir Crit Care Med. .

Abstract

Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one medication to slow lung function decline in progressive pulmonary fibrosis, pulmonary fibrosis remains a disease with a high morbidity and mortality. In recognition of the need to catalyze ongoing advances and collaboration in the field of pulmonary fibrosis, the NHLBI, the Three Lakes Foundation, and the Pulmonary Fibrosis Foundation hosted the Pulmonary Fibrosis Stakeholder Summit on November 8-9, 2022. This workshop was held virtually and was organized into three topic areas: 1) novel models and research tools to better study pulmonary fibrosis and uncover new therapies, 2) early disease risk factors and methods to improve diagnosis, and 3) innovative approaches toward clinical trial design for pulmonary fibrosis. In this workshop report, we summarize the content of the presentations and discussions, enumerating research opportunities for advancing our understanding of the pathogenesis, treatment, and outcomes of pulmonary fibrosis.

Keywords: interstitial lung disease; pulmonary fibrosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Integration of multimodal risk factors for disease risk probability. The schematic illustrates the integration of imaging, clinical, and molecular information to determine disease risk for an individual patient. Disease risk could pertain to the development of pulmonary fibrosis for those with interstitial lung abnormalities or a family history of pulmonary fibrosis or to the development of disease progression for those with established pulmonary fibrosis.
Figure 2.
Figure 2.
Tools, diagnostics, and innovations to advance discovery, diagnosis, and drug development for pulmonary fibrosis. CT = computed tomography; EB-OCT = endobronchial optical coherence tomography; PCLS = precision-cut lung slices; PET = positron emission tomography.
See this image and copyright information in PMC

References

    1. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med . 2014;189:214–222. - PMC - PubMed
    1. King TE, Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. ASCEND Study Group A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med . 2014;370:2083–2092. - PubMed
    1. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. INPULSIS Trial Investigators Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med . 2014;370:2071–2082. - PubMed
    1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. INBUILD Trial Investigators Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med . 2019;381:1718–1727. - PubMed
    1. Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Königshoff M, Kolb M, et al. ATS Assembly on Respiratory Cell and Molecular Biology An official American Thoracic Society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol . 2017;56:667–679. - PMC - PubMed

Publication types